AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...
Background: A 57-year-old woman who received treatment with mantle irradiation and systemic chemotherapy for Hodgkin's lymphoma diagnosed ... sentinel lymph-node biopsy and fractionated partial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback